C.01.609 Notwithstanding the provisions of section C.01.401(a), the potency of an antibiotic in in amounts greater than 50 parts per million contained in a medicated feed registered under the Feeds Act may be declared in grams per ton.
C.01.610 No person shall sell any substance having oestrogenic activity for administration to poultry that may be consumed as food.
C.01.610.1 No person shall sell a drug for administration to animals that produce food or that are intended for consumption as food if that drug contains
(a) chloramphenicol or its salts or derivatives;
(b) a 5-nitrofuran compound;
(c) clenbuterol or its salts or derivatives;
(d) a 5-nitroimidazole compound; or
(e) diethylstilbestrol or other stilbene compounds.
- SOR/85-539, s. 1;
- SOR/85-685, s. 2;
- SOR/91-546, s. 1;
- SOR/94-568, s. 2;
- SOR/97-510, s. 2;
- SOR/2003-292, s. 3.
C.01.610.2 No person shall sell an antibiotic preparation containing chloramphenicol, its salts or derivatives, for administration to animals that do not produce food and that are not intended for consumption as food unless
(a) both the inner label and outer label of the preparation carry the words “WARNING: FEDERAL LAW PROHIBITS THE ADMINISTRATION OF THIS PREPARATION TO ANIMALS THAT PRODUCE FOOD OR ANIMALS THAT ARE INTENDED FOR CONSUMPTION AS FOOD / MISE EN GARDE : EN VERTU DES LOIS FÉDÉRALES, IL EST INTERDIT D’ADMINISTRER CETTE PRÉPARATION AUX ANIMAUX QUI PRODUISENT DES ALIMENTS OU AUX ANIMAUX DESTINÉS À ÊTRE CONSOMMÉS COMME ALIMENTS”;
(b) where the preparation is for parenteral use, the preparation contains, in the form of chloramphenicol sodium succinate, not more than one gram of chloramphenicol per vial;
(c) where the preparation is for ophthalmic use, the preparation contains not more than one per cent chloramphenicol; and
(d) where the preparation is for oral use, the preparation
- SOR/91-546, s. 1.
(a) to file with the Director in respect of that drug a submission describing in detail tests carried out to verify that the administration of the drug to an animal does not result in a substance named in column II of the List referred to in the Marketing Authorization for Maximum Residue Limits for Veterinary Drugs in Foods being present in a food set out in column III of the List, except in an amount within the maximum residue limit set out in column IV of the List in respect of the food and the substance; and
(b) to print on the principal display panel of the outer label, the inner label and the packaging insert, if any, that describes the drug, a warning that food derived from animals to which the drug has been administered must not be sold for human consumption unless there has elapsed since the administration of the drug a period of time specified by the Director, based on a review of the available data with respect to drug residues.
(2) No manufacturer shall sell a drug in respect of which the Director has required a warning to be printed pursuant to paragraph (1)(b) unless the manufacturer has complied with that request.
- SOR/93-467, s. 2;
- SOR/2016-74, s. 10.
C.01.612 [Repealed, SOR/94-568, s. 3]
C.01.625 Contraceptive drugs that are manufactured, sold or represented for use in the prevention of conception and that are not prescription drugs may be advertised to the general public.
- SOR/2013-122, s. 13.
DIVISION 1AEstablishment Licences
- active ingredient
active ingredient means a drug that, when used as a raw material in the fabrication of a drug in dosage form, provides its intended effect. (ingrédient actif)
- active pharmaceutical ingredient
active pharmaceutical ingredient means an active ingredient that is used in the fabrication of a pharmaceutical. (ingrédient actif pharmaceutique)
- antimicrobial agent
antimicrobial agent means a drug that is capable of destroying pathogenic micro-organisms and that is labelled as being for use in the disinfection of environmental surfaces or medical devices, as defined in the Medical Devices Regulations, that
- batch certificate
batch certificate means a certificate issued by the fabricator of a lot or batch of a drug that is exported within the framework of a mutual recognition agreement and in which the fabricator
(a) identifies the master production document for the drug and certifies that the lot or batch has been fabricated, packaged/labelled and tested in accordance with the procedures described in that document;
(b) provides a detailed description of the drug, including
(c) identifies the analytical methods used in testing the lot or batch and provides details of the analytical results obtained;
(d) sets out the addresses of the buildings at which the lot or batch was fabricated, packaged/labelled and tested; and
(e) certifies that the lot or batch was fabricated, packaged/labelled and tested in accordance with the good manufacturing practices of the regulatory authority that has recognized those buildings as meeting its good manufacturing practices standards. (certificat de lot)
- bulk process intermediate
bulk process intermediate means an active ingredient that is used in the fabrication of either a drug of biological origin that is listed in Schedule C to the Act or a drug that is listed in Schedule D to the Act. (produit intermédiaire en vrac)
- class monograph
class monograph means a document prepared by the Department of Health that
- dilute drug premix
dilute drug premix means a drug for veterinary use that results from mixing a drug premix with a feed as defined in section 2 of the Feeds Act, to such a level that at least 10 kg of the resulting mixture is required to medicate one tonne of complete feed, as defined in section 2 of the Feeds Regulations, 1983, with the lowest approved dosage level of the drug. (prémélange médicamenteux dilué)
- dosage form class
dosage form class means a parenteral, tablet, capsule, solution, suspension, aerosol, powder, suppository, medical gas or drug premix, or any other dosage form class designated by the Minister. (classe de forme posologique)
- drug premix
drug premix means a drug for veterinary use to which a drug identification number has been assigned, where the directions on its label specify that it is to be mixed with feed as defined in section 2 of the Feeds Act. (prémélange médicamenteux)
fabricate means to prepare and preserve a drug for the purposes of sale. (manufacturer)
import means to import into Canada a drug for the purpose of sale. (importer)
- MRA country
MRA country means a country that is a participant in a mutual recognition agreement with Canada. (pays participant)
- mutual recognition agreement
mutual recognition agreement means an international agreement that provides for the mutual recognition of compliance certification for good manufacturing practices for drugs. (accord de reconnaisance mutuelle)
package/label means to put a drug in its immediate container or to affix the inner or outer label to the drug. (emballer-étiqueter)
pharmaceutical means a drug other than a drug listed in Schedule C or D to the Act. (produit pharmaceutique)
- recognized building
recognized building means, in respect of the fabrication, packaging/labelling or testing of a drug, a building that a regulatory authority that is designated under subsection C.01A.019(1) in respect of that activity for that drug has recognized as meeting its good manufacturing practices standards in respect of that activity for that drug. (bâtiment reconnu)
- regulatory authority
regulatory authority means a government agency or other entity in an MRA country that has a legal right to control the use or sale of drugs within that country and that may take enforcement action to ensure that drugs marketed within its jurisdiction comply with legal requirements. (autorité réglementaire)
site[Repealed, SOR/2002-368, s. 1]
wholesale[Repealed, SOR/2013-74, s. 2]
wholesaler means a person who is not a distributor described in section C.01A.003 and who sells any of the following drugs other than at retail sale:
(2) In this Division and in Division 2, drug does not include a dilute drug premix, a medicated feed as defined in subsection 2(1) of the Feeds Regulations, 1983, an active ingredient that is for veterinary use or a drug that is used only for the purposes of an experimental study in accordance with a certificate issued under section C.08.015.
(3) Where the Minister designates additional dosage form classes, the Minister shall make a list of those classes available on request.
- SOR/97-12, s. 5;
- SOR/98-7, s. 1;
- SOR/2000-120, s. 1;
- SOR/2002-368, s. 1;
- SOR/2004-282, s. 1;
- SOR/2013-74, s. 2;
- SOR/2013-122, s. 14.
- Date modified: